Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review

Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review

Alternative title Teriparatida (hormônio recombinante humano da paratireóide 1-34) para mulheres com osteoporose pós-menopausa: revisão sistemática
Author Trevisani, Virginia Fernandes Moça Autor UNIFESP Google Scholar
Riera, Rachel Google Scholar
Imoto, Aline Mizusaki Google Scholar
Saconato, Humberto Google Scholar
Atallah, Álvaro Nagib Autor UNIFESP Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Univ Fed Rio Grande do Norte
Brazilian Cochrane Ctr
APM
Abstract CONTEXT AND OBJECTIVE: Osteoporosis is defined as a disease characterized by low bone mass and deterioration of the bone tissue microarchitecture. Teriparatide stimulates the formation and action of osteoblasts, which are responsible for bone formation, thus promoting bone tissue increase. The aim was to assess the effectiveness and safety of teriparatide for treating postmenopausal osteoporosis.METHODS: A systematic review was conducted using the Cochrane Collaboration methodology.RESULTS: 1) Teriparatide 20 mu g or 40 mu g versus placebo: there was a benefit from teriparatide, considering the following outcomes: reduction in the number of new vertebral and non-vertebral fractures, and increased whole-body, lumbar and femoral bone mineral density. 2) Teriparatide 40 mu g versus alendronate 10 mg/day for 14 months: there was no statistical difference regarding the incidence of new vertebral or non-vertebral fractures, although in the group that received teriparatide there was greater bone mineral density increase in the whole body, lumbar column and femur. 3) Estrogen plus teriparatide 25 mu g versus estrogen: there was a benefit, considering the following outcomes: reduction in the number of new vertebral fractures, and increased whole-body, lumbar and femoral bone mineral density after three years.CONCLUSIONS: When teriparatide is intermittently administered in low doses, it reduces the incidence of vertebral fractures (67%) and non-vertebral fractures (38%) and increases bone mineral density in the lumbar column and femur. There is a need for studies with longer observation in order to allow conclusions regarding the safety and duration of the therapeutic effects.
Keywords Osteoporosis
Fractures, bone
Postmenopause
Teriparatide
Review
Language English
Sponsor Department of Science and Technology of the Brazilian Ministry of Health
Date 2008-09-04
Published in Sao Paulo Medical Journal. Sao Paulo: Associacao Paulista Medicina, v. 126, n. 5, p. 279-284, 2008.
ISSN 1516-3180 (Sherpa/Romeo, impact factor)
Publisher Associacao Paulista Medicina
Extent 279-284
Origin http://dx.doi.org/10.1590/S1516-31802008000500007
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000262734600007
SciELO ID S1516-31802008000500007 (statistics in SciELO)
URI http://repositorio.unifesp.br/11600/45544

Show full item record




File

Name: S1516-31802008000500007.pdf
Size: 213.5Kb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account